Alfasigma S.p.A.
http://www.alfasigma.com/en
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alfasigma S.p.A.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.
Q1 2024 Posts Big M&A Total Led By Novo Holdings’ Catalent Takeout
The $16.5bn deal, intended to increase Novo Nordisk’s production of semaglutide-containing products, led a $36bn-plus quarter for M&A transactions, according to Evaluate.
Two Avian Flu Vaccines Among 10 New Products To Get EMA Nod
The European Medicines Agency has OKd two new H5N1 jabs, including a pandemic preparedness vaccine intended for use only if a flu pandemic is declared. Eight other products are also heading for EU-wide approval.
AstraZeneca’s Danicopan Among Four Orphans Up For EU Approval Decision
The European Medicines Agency is due to decide whether to back pan-EU marketing authorization for 11 new products, including four orphan drugs.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- ALFASIGMA
- Defiante Farmaceutica S.A.
- Sigma-Tau Pharma Ltd
- Sigma-Tau Arzneimittel GmbH
- Sigma-Tau Research Switzerland SA
- Biofutura Pharma S.p.A.
- Alfa Wassermann SpA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice